Drug intelligence / Profile preview

TMED9 siRNA

Development stage
Preclinical
Lead developer
Santa Cruz Biotechnology
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Parenteral
01

Overview

TMED9 siRNA is a research-grade small interfering RNA (siRNA) designed to knock down the expression of the TMED9 gene in cellular models. TMED9, also known as Transmembrane Emp24 Domain-containing Protein 9, is a cargo receptor located within the early secretory pathway (endoplasmic reticulum-Golgi intermediate compartment) that facilitates the bidirectional trafficking of various proteins, including EGFR, TGF-α, and WNT. In preclinical research, TMED9 siRNA has been utilized to investigate the role of TMED9 in several solid tumors, such as glioma, glioblastoma, and breast cancer, where the protein is frequently upregulated and associated with poor patient survival. By silencing TMED9, researchers have demonstrated a significant reduction in the migratory and invasive capacities of cancer cell lines. Additionally, it is used as a laboratory tool to study protein quality control mechanisms, specifically the clearance of misfolded GPI-anchored proteins from the endoplasmic reticulum.

Other names
TMED9 small interfering RNATMED-9 small interfering RNATMED 9 small interfering RNATransmembrane Emp24 Domain-containing Protein 9 siRNA
02

Targets

Transmembrane p24 trafficking protein 9 mRNA

Beyond the preview

Go deeper on TMED9 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TMED9 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call